THCA and delta-9-THC are rapidly becoming one of the most widely discussed cannabinoids in research today. Protonify, a leading global B2B provider of high purity cannabinoids, announced the launch of its Global Cannabinoid Research Partnership campaign designed to engage the world’s leading researchers investigating the medicinal and therapeutic efficacy of the cannabinoids.
Under the new program, Protonify of Nanoose Bay, BC is providing cannabis researchers complimentary access to its high-purity, pharmaceutical-grade cannabinoids, including it delta-9-THC concentrate (96%+ purity) and its THCA isolate at purity levels that approach 100%.
The cannabinoids are produced with Protonify’s organic chemistry-based process, which the Canadian company says differs from other cannabis extraction technique being used today. The company says its patent-pending process results in the kind of consistent, high-quality products required for clinical cannabinoid research.
“One of the greatest challenges that cannabis researchers face is the lack of consistent, high-quality cannabinoid inputs”, said Andrew Fisher, CEO of Protonify. “Cannabinoid ingredients that have been sourced from traditional cannabis extractors contain high levels of unknown impurities, are unstable, and critically, have different profiles from one batch to the next. Protonify solves these problems.”
Research to date has uncovered many potential benefits for THCA, including anti-inflammatory, antioxidant, antiemetic, analgesic properties, and as a neuroprotective without the unwanted psychoactive effects of THC. According to Forbes, delta-9-THC’s potential benefits include: Relaxation, anxiety relief, increased appetite and mood elevation.
Interested partners should contact Protonify at info@protonify.com.